Retire early with these 2 healthcare stocks

Bilaal Mohamed looks at two healthcare stocks that should benefit from an ageing population.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Since I last recommended the shares in December, medical equipment manufacturer Smith & Nephew (LSE: SN) has seen its share price surge 11%. That’s quite a performance from a relatively stable FTSE 100 company within just three months. So what now? Is this global medical technology business still a buy after its recent gain?

Currency headwinds

Last month the group issued its full year results for 2016 and, truth be told, I found them a little disappointing. Group revenues came in at $4,669m, an increase of just 1% on a reported basis and 2% on an underlying basis. This was largely due to foreign currency and disposal-related headwinds. However, there were encouraging performances in areas such as Sports Medicine and Knee Implants, where its products maintained strong momentum.

Market conditions in China and the Gulf States were particularly challenging during the first six months of the year, but China did return to growth, as did Emerging Markets as a whole during the second half of the year. Management have acknowledged the rather subdued performance, but are confident of a stronger performance this year, anticipating underlying revenue growth of between 3%-4% for 2017.

Ageing populations

My view on Smith & Nephew hasn’t changed. Ageing populations in developed markets and improving incomes in emerging markets should contribute to continued volume growth in all of the company’s businesses. Furthermore, healthcare systems and hospital infrastructure in the developing world is improving at the considerable pace, which should help the group’s sales over the longer term.

Personally I view Smith & Nephew as a fairly defensive business, with plenty of opportunity for further growth both in developed nations and emerging markets, albeit at a slow but steady pace. The shares trade on a P/E rating of 18.1 falling to 16.5 by next year, which isn’t too demanding for a high quality blue-chip like Smith & Nephew.

Good start to the year

Meanwhile, another healthcare firm whose shares have been performing well recently is UDG Healthcare (LSE: UDG). The Dublin-based group has made a good start to fiscal 2017 with operating profits for the first quarter well ahead of last year, driven by continued growth and the impact of acquisitions.

In its first quarter update the group said that its Ashfield business, which commercialises services for the pharmaceutical and healthcare industry, traded well ahead of the same period last year. Growth was supplemented by acquisitions, such as STEM Marketing which it acquired in October. In its Sharp packaging services business operating profits were moderately ahead of last year, with the Aquilant sales & marketing business remaining in line with the same quarter last year.

Strong growth is set to continue with consensus forecasts predicting a double digit rise in earnings in each of the next two next two years, but still leaving the shares on a premium P/E rating of 23 for FY 2018. I see UDG as a riskier play than Smith & Nephew, but one that could reap higher rewards if the strong growth continues.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Bilaal Mohamed has no position in any shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

British union jack flag and Parliament house at city of Westminster in the background
Investing Articles

Labour winning the general election would be positive for UK stocks, says JP Morgan

One mega-bank thinks certain UK stocks could benefit following the 4 July election. This writer considers a FTSE share that…

Read more »

Older couple walking in park
Investing Articles

No savings at 40? Here’s how I’d aim to retire comfortably with FTSE 100 stocks

It's never too late to begin investing in FTSE 100 stocks for retirement. Royston Wild reveals three steps to help…

Read more »

Young Asian man drinking coffee at home and looking at his phone
Investing Articles

Down 17%, is National Grid’s share price a FTSE 100 bargain?

National Grid's share price has taken a battering following a multi-billion-pound rights issue and dividend rebasement. Is it now too…

Read more »

Environmental technology concept
Investing Articles

Up 150% this year! Can NVIDIA stock keep on soaring?

Christopher Ruane explains why NVIDIA stock has soared over 150% already this year, where it might be going -- and…

Read more »

Investing Articles

Down 44% in a year, here’s why the Aston Martin share price could keep struggling

Not only has the Aston Martin share price collapsed in recent years, our writer sees its current business performance as…

Read more »

Investing Articles

I’m considering these 2 high-growth stocks to buy as a technology investor

Our author thinks Kainos and Softcat could be two of Britain's best tech investments. He thinks the risks in the…

Read more »

Abstract 3d arrows with rocket
Investing Articles

A once-in-a-decade opportunity to buy these FTSE 100 growth shares before they rocket?

Our writer highlights two FTSE 100 growth stocks he thinks could seriously outperform as interest rates are cut and economic…

Read more »

Portrait of elderly man wearing white denim shirt and glasses looking up with hand on chin. Thoughtful senior entrepreneur, studio shot against grey background.
Investing For Beginners

Down 14% in a month, is this the FTSE 100’s biggest bargain right now?

Jon Smith mulls over whether he should buy one of the worst-performing FTSE 100 stocks based on it being an…

Read more »